CoChat

Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development

Open access

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

In May 2022, there is an International Regulatory and Pharmaceutical Industry (Innovation and Quality [IQ] Microphysiological Systems [MPS] Affiliate) Workshop on the standardization of complex in vitro models (CIVMs) in drug development. This manuscript summarizes the discussions and conclusions of this joint workshop organized and executed by the IQ MPS Affiliate and the United States Food and Drug Administration (FDA). A key objective of the workshop is to facilitate discussions around opportunities and/or needs for standardization of MPS and chart potential pathways to increase model utilization in the context of regulatory decision making. Participation in the workshop included 200 attendees from the FDA, IQ MPS Affiliate, and 26 global regulatory organizations and affiliated parties representing Europe, Japan, and Canada. It is agreed that understanding global perspectives regarding the readiness of CIVM/MPS models for regulatory decision making and potential pathways to gaining acceptance is useful to align on globally. The obstacles are currently too great to develop standards for every context of use (COU). Instead, it is suggested that a more tractable approach may be to think of broadly applicable standards that can be applied regardless of COU and/or organ system. Considerations and next steps for this effort are described.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/adbi.202300131

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 6

  1. Baran S. W., 2022, ALTEX, 39
  2. Wang X., 2022, ALTEX
  3. Ramsden D., 2022, ALTEX, 39, 273
  4. a)I. S. (R3) Vol. 2022 2020;
  5. b)I. S10 Vol. 2022 2014.
  6. FDA Vol. 2022 2022.

Cited by

See all 44

Metadata

Authors
Tomlinson, L., Ramsden, D., Leite, S. B., Beken, S., Bonzo, J. A., Brown, P., Candarlioglu, P. L., Chan, T. S., Chen, E., Choi, C. K., David, R., Delrue, N., Devine, P. J., Ford, K., Garcia, M. I., Gosset, J. R., Hewitt, P., Homan, K., Irrechukwu, O., Kopec, A. K., Liras, J. L., Mandlekar, S., Raczynski, A., Sadrieh, N., Sakatis, M. Z., Siegel, J., Sung, K., Sunyovszki, I., Van Vleet, T. R., Ekert, J. E., & Hardwick, R. N.
Affiliations
  • Pfizer (United States) (US)
  • DMPK Oncology AstraZeneca Boston MA 02451 USA
  • European Commission (BE)
  • Federal Agency for Medicines and Health Products Brussels 1210 Belgium
  • United States Food and Drug Administration (US)
  • GlaxoSmithKline (United Kingdom) (GB)
  • Boehringer Ingelheim (United States) (US)
  • Genentech (US)
  • Biogen (United States) (US)
  • AstraZeneca (United Kingdom) (GB)
  • Organisation de Coopération et de Développement Economiques (FR)
  • Bristol-Myers Squibb (United States) (US)
  • Merck Healthcare KGaA, Darmstadt (Germany) (DE)
  • Johnson & Johnson (United States) (US)
  • Vertex Pharmaceuticals (United States) (US)
  • Center for Biologics Evaluation and Research (US)
  • AbbVie, Inc. North Chicago IL 60064 USA
  • UCB Pharma Cambridge MA 02140 USA
Corresponding author
  • Tomlinson, Lindsay
  • Ekert, Jason E.
  • Hardwick, Rhiannon N.
Venue
Advanced Biology
Publisher
Wiley
Published
2023-10-09
Volume
8
Issue
8
Pages
e2300131-e2300131
ISSN
2701-0198 (ISSN-L)
OpenAlex
W4387473497
Cited by
33
References
54
Citations by year
2026: 12 · 2025: 13 · 2024: 6 · 2023: 2
FWCI
2.60
Type
journal article
Language
en
Open access
Locations
  • Advanced Biology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • European Food Safety Authority
  • U.S. Food and Drug Administration
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
Keywords
microphysiological systems, standardization, regulatory decision-making, drug development, regulatory acceptance, context of use, FDA
MeSH terms
Drug Development, Drug Industry, Humans, United States, United States Food and Drug Administration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development. https://app.cochat.ai/papers/10.1002/adbi.202300131
The paper
Tomlinson, L., Ramsden, D., Leite, S. B., Beken, S., Bonzo, J. A., Brown, P., Candarlioglu, P. L., Chan, T. S., Chen, E., Choi, C. K., David, R., Delrue, N., Devine, P. J., Ford, K., Garcia, M. I., Gosset, J. R., Hewitt, P., Homan, K., Irrechukwu, O., . . . Hardwick, R. N. (2024). Considerations from an International Regulatory and Pharmaceutical Industry (IQ MPS Affiliate) Workshop on the Standardization of Complex In Vitro Models in Drug Development. Advanced Biology. https://doi.org/10.1002/adbi.202300131

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.